Bosentan 6.25-mg/mL Oral Suspension
Download in electronic PDF format for $75
Abstract: A formulation for preparing Bosentan 6.25-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.
Related Keywords:
formulation, hazardous medication, pulmonary arterial hypertension, bosentan, exercise capacity
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Bosentan 6.25-mg/mL Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2016
Pg. 505
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
Basics of Compounding for Cough
Allen Loyd V Jr
|
Nov/Dec 2004
Pg. 462-465
|
Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil?
Wung Deanna
|
Jan/Feb 2013
Pg. 24-27
|
Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis
Muller George, Young Thomas W, Reina Rachel, Caldwell Delmar R
|
Jan/Feb 2010
Pg. 40-45
|
Application of Sildenafil for Pulmonary Hypertension in Canines and Foals
Davidson Gigi S
|
Nov/Dec 2006
Pg. 405-408
|
Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules
Allen Loyd V Jr
|
Mar/Apr 2016
Pg. 145
|
Ergoloid Mesylates 15-mg/mL and Selegiline HCl 6.25-mg/mL in PLO
Allen Loyd V Jr
|
May/Jun 2002
Pg. 203
|
Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension
Helms Scott R, Fox Samantha, Mixon William, Vail Jane
|
Jan/Feb 2012
Pg. 34-41
|
Medications Discontinued in the United States
Ashworth Lisa D
|
Jul/Aug 2002
Pg. 286-287
|
Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 43
|
Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 44
|
Nitazoxanide 20-mg/mL Oral Suspension
Allen Loyd V Jr
|
Sep/Oct 2023
Pg. 420
|
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension
|
May/Jun 2018
Pg. 263
|
Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 47
|
Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 415
|
Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
|
Sep/Oct 2021
Pg. 416
|
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 503
|
Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Nov/Dec 2021
Pg. 505
|
| Return to Top |
